Paper Details

  1. Home
  2. Paper Details

Effects of Lumacaftor-Ivacaftor on Airway Microbiota-Mycobiota and Inflammation in Patients with Cystic Fibrosis Appear To Be Linked to Pseudomonas aeruginosa Chronic Colonization.

Author: , BuiStéphanie, BurgelPierre-Régis, CharpentierElena, DelhaesLaurence, EnaudRaphael, FayonMichael, GuiraudJennifer, Héry-ArnaudGeneviève, Lussac-SortonFlorian, NikolskiMacha, SchaeverbekeThierry, Velo-SuárezLourdes

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Lumacaftor-ivacaftor, a CFTR modulator combination for cystic fibrosis (CF), was found to improve body mass index and reduce intravenous antibiotic courses. However, significant changes in airway microbiota-mycobiota and inflammation were not observed overall. Notably, in patients not chronically colonized with Pseudomonas aeruginosa, a significant increase in bacterial alpha-diversity and lower calprotectin levels were observed. This study suggests that CFTR modulators should be initiated early, ideally before chronic colonization with P. aeruginosa, to potentially improve airway microbiome and reduce inflammation.
Paper Details　
Original Abstract of the Article :
Lumacaftor-ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination approved for patients with cystic fibrosis (CF) who are homozygous for the F508del allele. This treatment showed significant clinical improvement; however, few studies have addressed the evolut...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100832/

データ提供：米国国立医学図書館（NLM）

The Impact of Lumacaftor-Ivacaftor on Airway Microbiota and Inflammation in Cystic Fibrosis Patients

Lumacaftor-ivacaftor, a combination therapy for cystic fibrosis (CF), has shown promise in improving lung function and reducing symptoms. This study investigates the impact of this treatment on the airway microbiota-mycobiota and inflammation in CF patients.

Lumacaftor-Ivacaftor: A Complex Impact on Airway Microbiota

The researchers found that lumacaftor-ivacaftor treatment resulted in significant improvements in body mass index and reduced intravenous antibiotic courses. However, the study also revealed a complex impact on the airway microbiota-mycobiota, with the evolution of the airway ecosystem depending on the patient's characteristics at treatment initiation, particularly the presence of chronic colonization with Pseudomonas aeruginosa.

Early Intervention: A Key to Success

This study emphasizes the importance of early initiation of CFTR modulator therapy, ideally before chronic colonization with P. aeruginosa. The researchers suggest that early intervention with lumacaftor-ivacaftor may help to maintain a more balanced airway microbiota and reduce the risk of persistent inflammation and lung damage.

Dr. Camel's Conclusion

Just as a camel adapts to the ever-changing desert landscape, CF patients require a personalized approach to treatment. This study provides valuable insights into the impact of lumacaftor-ivacaftor on the airway ecosystem, highlighting the importance of early intervention for optimizing patient outcomes.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-04-15
Further Info :

Pubmed ID

36971560

DOI: Digital Object Identifier

PMC10100832

Related Literature

Article Analysis
・Effects of ivacaftor
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.